BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 26437693)

  • 21. TET2 deletions are a recurrent but rare phenomenon in myeloid malignancies and are frequently accompanied by TET2 mutations on the remaining allele.
    Bacher U; Weissmann S; Kohlmann A; Schindela S; Alpermann T; Schnittger S; Kern W; Haferlach T; Haferlach C
    Br J Haematol; 2012 Jan; 156(1):67-75. PubMed ID: 22017486
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Significance of JAK2 and TET2 mutations in myelodysplastic syndromes.
    Hellström-Lindberg E
    Blood Rev; 2010 Mar; 24(2):83-90. PubMed ID: 20171768
    [TBL] [Abstract][Full Text] [Related]  

  • 23. High incidence of biallelic point mutations in the Runt domain of the AML1/PEBP2 alpha B gene in Mo acute myeloid leukemia and in myeloid malignancies with acquired trisomy 21.
    Preudhomme C; Warot-Loze D; Roumier C; Grardel-Duflos N; Garand R; Lai JL; Dastugue N; Macintyre E; Denis C; Bauters F; Kerckaert JP; Cosson A; Fenaux P
    Blood; 2000 Oct; 96(8):2862-9. PubMed ID: 11023523
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mutation in TET2 in myeloid cancers.
    Tefferi A; Lim KH; Levine R
    N Engl J Med; 2009 Sep; 361(11):1117; author reply 1117-8. PubMed ID: 19741235
    [No Abstract]   [Full Text] [Related]  

  • 25. p53 mutations in leukemia and myelodysplastic syndrome after ovarian cancer.
    Leonard DG; Travis LB; Addya K; Dores GM; Holowaty EJ; Bergfeldt K; Malkin D; Kohler BA; Lynch CF; Wiklund T; Stovall M; Hall P; Pukkala E; Slater DJ; Felix CA
    Clin Cancer Res; 2002 May; 8(5):973-85. PubMed ID: 12006509
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Genetic and chromosomal abnormalities in myelodysplastic syndrome].
    Mitani K
    Nihon Rinsho; 2012 Apr; 70 Suppl 2():108-12. PubMed ID: 23133937
    [No Abstract]   [Full Text] [Related]  

  • 27. [Mutations in TET2 in myeloid cancers].
    Bernard OA; Delhommeau F; Fontenay M; Vainchenker W
    Med Sci (Paris); 2009 Oct; 25(10):785-8. PubMed ID: 19849974
    [No Abstract]   [Full Text] [Related]  

  • 28. Case report: A novel TET2 mutation in a patient with refractory cytopenia with multilineage dysplasia.
    Coutinho DF; Diniz C; Filgueiras RL; Baptista RL; Ayres-Silva JP; Monte-Mór BC; Bonamino MH; Zalcberg IR
    Genet Mol Res; 2013 Nov; 12(4):5858-62. PubMed ID: 24301955
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cryptic aberrations may allow more accurate prognostic classification of patients with myelodysplastic syndromes and clonal evolution.
    Svobodova K; Lhotska H; Hodanova L; Pavlistova L; Vesela D; Belickova M; Vesela J; Brezinova J; Sarova I; Izakova S; Lizcova L; Siskova M; Jonasova A; Cermak J; Michalova K; Zemanova Z
    Genes Chromosomes Cancer; 2020 Jul; 59(7):396-405. PubMed ID: 32170980
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Necrotizing myopathy associated with TET2-mutated myelodysplastic syndrome.
    Dietrich T; de Mornac D; Garnier A; Espitia A; Néel A; Normand A; Toquet C; Agard C
    QJM; 2022 Sep; 115(9):633-634. PubMed ID: 35689623
    [No Abstract]   [Full Text] [Related]  

  • 31. Phenotypic correlates and prognostic outcomes of TET2 mutations in myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes: A comprehensive study of 504 adult patients.
    Coltro G; Antelo G; Lasho TL; Finke CM; Pardanani A; Gangat N; Carr RM; Binder M; Mangaonkar AA; Ketterling R; Fernandez-Zapico ME; Robertson KD; Bosi A; Vannucchi AM; Tefferi A; Patnaik MM
    Am J Hematol; 2020 Apr; 95(4):E86-E89. PubMed ID: 31925810
    [No Abstract]   [Full Text] [Related]  

  • 32. Philadelphia-positive dimorphic blasts in mixed-phenotype acute leukemia with TET2 mutation.
    Jain P; Tang G; Huh YO; Yin CC; Zuo Z; Pemmaraju N; Estrov Z; Daver N
    Am J Hematol; 2016 Jun; 91(6):647-8. PubMed ID: 26799924
    [No Abstract]   [Full Text] [Related]  

  • 33. [Recent advances of molecular mechanisms influencing prognosis of myelodysplastic syndrome - review].
    Guo J; Chang CK; Li X
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Aug; 20(4):1020-4. PubMed ID: 22931676
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A genetic development route analysis on MDS subset carrying initial epigenetic gene mutations.
    Li X; Xu F; Wu LY; Zhao YS; Guo J; He Q; Zhang Z; Chang CK; Wu D
    Sci Rep; 2020 Jan; 10(1):826. PubMed ID: 31964915
    [TBL] [Abstract][Full Text] [Related]  

  • 35. TET2 mutations in acute myeloid leukemia (AML): results from a comprehensive genetic and clinical analysis of the AML study group.
    Gaidzik VI; Paschka P; Späth D; Habdank M; Köhne CH; Germing U; von Lilienfeld-Toal M; Held G; Horst HA; Haase D; Bentz M; Götze K; Döhner H; Schlenk RF; Bullinger L; Döhner K
    J Clin Oncol; 2012 Apr; 30(12):1350-7. PubMed ID: 22430270
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Mutation of tet2 gene and malignant blood disease].
    Qian XF; Shen YF; Zhang SJ; Li JY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Aug; 18(4):1096-100. PubMed ID: 20723337
    [TBL] [Abstract][Full Text] [Related]  

  • 37. TP53 mutation does not confer a poor outcome in adult patients with acute lymphoblastic leukemia who are treated with frontline hyper-CVAD-based regimens.
    Kanagal-Shamanna R; Jain P; Takahashi K; Short NJ; Tang G; Issa GC; Ravandi F; Garcia-Manero G; Yin CC; Luthra R; Patel KP; Khoury JD; Montalban-Bravo G; Sasaki K; Kadia TM; Borthakur G; Konopleva M; Jain N; Garris R; Pierce S; Wierda W; Estrov Z; Cortes J; O'Brien S; Kantarjian HM; Jabbour E
    Cancer; 2017 Oct; 123(19):3717-3724. PubMed ID: 28608976
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Insufficient outcomes with imatinib mesylate: case report of Ph-positive acute myeloid leukemia evolving from myelodysplastic syndrome.
    Isoda A; Nakahashi H; Hoshino T; Mitsui T; Yoshida Y
    Am J Hematol; 2007 Jun; 82(6):501-2. PubMed ID: 17301971
    [No Abstract]   [Full Text] [Related]  

  • 39. Incidence of 17p deletions and TP53 mutation in myelodysplastic syndrome and acute myeloid leukemia with 5q deletion.
    Sebaa A; Ades L; Baran-Marzack F; Mozziconacci MJ; Penther D; Dobbelstein S; Stamatoullas A; Récher C; Prebet T; Moulessehoul S; Fenaux P; Eclache V
    Genes Chromosomes Cancer; 2012 Dec; 51(12):1086-92. PubMed ID: 22933333
    [TBL] [Abstract][Full Text] [Related]  

  • 40. TET2 mutations in myelodysplasia and myeloid malignancies.
    Mullighan CG
    Nat Genet; 2009 Jul; 41(7):766-7. PubMed ID: 19557078
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.